Related Experiment Videos
Accidental overdose of mitoxantrone in three patients
W Siegert1, W Hiddemann, R Koppensteiner
1Medizinische Klinik und Poliklinik, Klinikum Rudolf Virchow, Freie Universität Berlin, F.R.G.
Abstract:
Mitoxantrone is a new effective antineoplastic agent with activity against a wide range of tumors. Compared with the anthracycline drugs doxo- and daunorubicin, it exhibits a clearly lower toxicity and, most importantly, a reduced cardiotoxicity. The analysis of the side-effects recorded after accidental overdosage of the drug gives additional insight into its tolerability. Here we describe our observations in three patients who inadvertently received 100 mg m-2 (two pts) and 183 mg m-2 (one pt) as single slow bolus injections. The main side-effects were moderate nausea and vomiting, shaking chills, and profound but reversible neutro- and thrombocytopenia. There was no immediate cardiac toxicity. One patient with extensive previous daunomycin exposure developed congestive heart failure after 4 months. Two patients were not evaluable for late cardiac complications because of early death due to tumor progression.
Insights
Mitoxantrone shows reduced toxicity and cardiotoxicity compared to anthracyclines. Accidental high-dose exposure revealed manageable side effects like nausea and reversible neutropenia, with delayed cardiac issues in one patient.
Area of Science:
- Oncology
- Pharmacology
Background:
- Mitoxantrone is an effective antineoplastic agent with a favorable toxicity profile compared to anthracyclines.
- Reduced cardiotoxicity is a key advantage of mitoxantrone over doxorubicin and daunorubicin.
Observation:
- Three patients received accidental high doses of mitoxantrone (100-183 mg m-2).
- Observed side effects included nausea, vomiting, chills, and reversible neutropenia and thrombocytopenia.
- No immediate cardiac toxicity was noted.
Findings:
- High-dose mitoxantrone administration resulted in moderate, transient side effects.
- One patient with prior daunomycin exposure developed congestive heart failure 4 months post-treatment.
- Two patients were not evaluable for late cardiac effects due to early mortality from tumor progression.
Implications:
- Mitoxantrone demonstrates a generally good tolerability profile, even at supratherapeutic doses.
- Potential for delayed cardiotoxicity exists, particularly in patients with prior anthracycline exposure.
- Further investigation into long-term cardiac safety is warranted.